Reaction

Pulmonary Mucormycosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 509 reports · 38 co-occurring drugs

As of the last recalculation, Pulmonary Mucormycosis appears in 509 FAERS reports alongside 38 co-occurring drug terms. The strongest observed disproportionality signal is MICAFUNGIN SODIUM (PRR 232.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Micafungin Sodium	44	232.2	233.4
Amphotericin B	57	209.4	210.3
Voriconazole Injection	84	189.3	190.0
Posaconazole Delayed-Release	37	148.5	149.0
Tacrolimus Ointment 0.1%	232	139.2	139.4
Voriconazole	86	139.1	139.5
Tacrolimus Extended-Release Capsules	232	138.8	139.0
Remdesivir	36	118.8	119.1
Anti-Thymocyte Globulin (Rabbit)	22	116.5	116.8
Posaconazole	42	115.1	115.4
Tacrolimus	235	113.1	113.3
Valganciclovir Hydrochloride Powder,	29	103.0	103.3
Mycophenolate Mofetil	192	92.2	92.3
Mycophenolate Mofetil Hydrochloride	192	92.1	92.2
Basiliximab	25	91.4	91.6
Valganciclovir	34	79.0	79.1
Valganciclovir Hydrochloride	34	79.0	79.1
Mycophenilic Acid	37	78.7	78.8
Methylprednisolone	133	52.9	53.0
Piperacillin Sodium,Tazobactam Sodium	32	52.6	52.6
Mycophenolic Acid	38	52.4	52.4
Pegaspargase	14	48.1	48.1
Oseltamivir	9	47.0	47.1
Sirolimus	15	46.9	46.9
Linezolid	26	37.6	37.6
Fludarabine Phosphate	32	35.4	35.5
Cefepime	11	32.0	32.1
Mercaptopurine	13	31.4	31.5
Atovaquone	6	30.8	30.8
Meropenem	23	30.6	30.7
Piperacillin And Tazobactam	9	29.3	29.3
Cefepime Hydrochloride	11	28.5	28.5
Thiotepa	6	26.0	26.0
Azacitidine For	9	20.6	20.6
Azacitidine	13	18.4	18.4
Ruxolitinib	26	15.6	15.6
Venetoclax	19	13.1	13.1
Axicabtagene Ciloleucel	3	12.5	12.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.